JAMES RIDDLE: Open Payments
NPI 1225003973 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$484 in 24 payments from 8 companies in 2025. Trend: 2023 $866 · 2024 $1,181 · 2025 $484
Food & beverage: $484
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $120 |
| Otsuka America Pharmaceutical, Inc. | 5 | $81 |
| Alkermes, Inc. | 4 | $81 |
| E.R. Squibb & Sons, L.L.C. | 4 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| ABBVIE INC. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: INGREZZA, COBENFY, ARISTADA, CAPLYTA, ABILIFY MAINTENA, LYBALVI, ABILIFY ASIMTUFII, HETLIOZ.
Industry payments across SC — which companies pay providers there.
